Invention Grant
- Patent Title: Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
-
Application No.: US15552556Application Date: 2016-02-24
-
Publication No.: US10214530B2Publication Date: 2019-02-26
- Inventor: Michael Bader , Edgar Specker , Susann Matthes , Anja Schütz , Keven Mallow , Maik Grohmann , Marc Nazaré
- Applicant: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN , FORSCHUNGSVERBUND BERLIN E.V.
- Applicant Address: DE Berlin
- Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN
- Current Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN
- Current Assignee Address: DE Berlin
- Agency: Norris McLaughlin, PA
- Priority: EP15156418 20150224
- International Application: PCT/EP2016/053872 WO 20160224
- International Announcement: WO2016/135199 WO 20160901
- Main IPC: C07D473/06
- IPC: C07D473/06 ; C07D487/04 ; C07D519/00 ; A61K31/522 ; A61P3/04 ; A61P11/06 ; A61P19/10 ; A61P25/18 ; A61P25/24 ; A61P29/00 ; A61P35/00
Abstract:
The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.
Public/Granted literature
- US20180051025A1 XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME Public/Granted day:2018-02-22
Information query
